Petra Brhlikova (P Brhlikova)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Drug Administration

Major Depressive Disorder

Arterial Hypertension

Top Venues

Journal of pharmaceutical policy and practice

Journal of the Royal Society of Medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Deborah Babatunde, Allyson M Pollock, Moses Ocan, Petra Brhlikova
Audit of essential medicine listing and registration status of medicines on standard treatment guidelines in Kenya, Tanzania and Uganda: Case study of malaria, tuberculosis, hypertension and type 2 diabetes mellitus. JRSM open 15 (3) (2024)
Ereel Ayubi, Rosanna Lyus, Petra Brhlikova, Allyson M Pollock
A critical appraisal of the quality of data submitted by sub-Saharan African cancer registries to GLOBOCAN 2020. JRSM open 15 (1) (2024)
David Kamiab Hesari, Saleh Aljadeeah, Petra Brhlikova, Dalia Hyzam, Henry Komakech, Jhon Sebastián Patiño Rueda, Jovana Ocampo Cañas, Carly Ching, Samuel Orubu, Oscar Bernal Acevedo, Huda Basaleem, Christopher Garimoi Orach, Muhammad Zaman, Clarissa Prazeres da Costa
Access to and utilisation of antimicrobials among forcibly displaced persons in Uganda, Yemen and Colombia: a pilot cross-sectional survey. BMJ open 14 (7) (2024)
David Kamiab Hesari, Saleh Aljadeeah, Petra Brhlikova, Dalia Hyzam, Henry Komakech, Jhon Sebastián Patiño Rueda, Jovana Ocampo Cañas, Carly Ching, Samuel Orubu, Oscar Bernal Acevedo, Huda Basaleem, Christopher Garimoi Orach, Muhammad Zaman, Clarissa Prazeres da Costa
Access to and utilisation of antimicrobials among forcibly displaced persons in Uganda, Yemen and Colombia: a pilot cross-sectional survey. BMJ open 14 (7) (2024)
Ereel Ayubi, Rosanna Lyus, Petra Brhlikova, Allyson M Pollock
A critical appraisal of the quality of data submitted by sub-Saharan African cancer registries to GLOBOCAN 2020. JRSM open 15 (1) (2024)
David Kamiab Hesari, Saleh Aljadeeah, Petra Brhlikova, Dalia Hyzam, Henry Komakech, Jhon Sebastián Patiño Rueda, Jovana Ocampo Cañas, Carly Ching, Samuel Orubu, Oscar Bernal Acevedo, Huda Basaleem, Christopher Garimoi Orach, Muhammad Zaman, Clarissa Prazeres da Costa
Access to and utilisation of antimicrobials among forcibly displaced persons in Uganda, Yemen and Colombia: a pilot cross-sectional survey. BMJ open 14 (7) (2024)
Deborah Babatunde, Allyson M Pollock, Moses Ocan, Petra Brhlikova
Audit of essential medicine listing and registration status of medicines on standard treatment guidelines in Kenya, Tanzania and Uganda: Case study of malaria, tuberculosis, hypertension and type 2 diabetes mellitus. JRSM open 15 (3) (2024)
Rosanna Lyus, C Buamah, Allyson M Pollock, L Cosgrove, Petra Brhlikova
Global Burden of Disease 2017 estimates for Major Depressive Disorder: a critical appraisal of the epidemiological evidence. JRSM open 14 (9) (2023)
A Green, Rosanna Lyus, M Ocan, Allyson M Pollock, Petra Brhlikova
Registration of essential medicines in Kenya, Tanzania and Uganda: a retrospective analysis. Journal of the Royal Society of Medicine (2023)
Petra Brhlikova, Aashna Mehta, Patricia McGettigan, Allyson M Pollock, Peter Roderick, Habib Hasan Farooqui
Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics. Journal of pharmaceutical policy and practice 16 (1) (2023)
Petra Brhlikova, Thilagawathi Abi Deivanayagam, Zaheer Ud-Din Babaar, Claudia Garcia Serpa Osorio-de-Castro, Rosangela Caetano, Allyson M Pollock
Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation. Journal of pharmaceutical policy and practice 16 (1) (2023)
Petra Brhlikova, Karen Maigetter, Jude Murison, Amon G Agaba, Jonans Tusiimire, Allyson M Pollock
Registration and local production of essential medicines in Uganda. Journal of pharmaceutical policy and practice 13 (2020)
Catherine Schuster Bruce, Petra Brhlikova, Joseph Heath, Patricia McGettigan
The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS medicine 16 (9) (2019)